| 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety AK Davis, S So, R Lancelotta, JP Barsuglia, RR Griffiths The American journal of drug and alcohol abuse 45 (2), 161-169, 2019 | 128 | 2019 |
| The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption AK Davis, JP Barsuglia, R Lancelotta, RM Grant, E Renn Journal of Psychopharmacology 32 (7), 779-792, 2018 | 128 | 2018 |
| Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study J Barsuglia, AK Davis, R Palmer, R Lancelotta, AM Windham-Herman, ... Frontiers in psychology 9, 2459, 2018 | 71 | 2018 |
| Psychedelic treatment for trauma-related psychological and cognitive impairment among US special operations forces veterans AK Davis, LA Averill, ND Sepeda, JP Barsuglia, T Amoroso Chronic Stress 4, 2470547020939564, 2020 | 63 | 2020 |
| Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine BJ Malcolm, M Polanco, JP Barsuglia Journal of Psychoactive Drugs 50 (3), 256-265, 2018 | 53 | 2018 |
| Subjective effectiveness of ibogaine treatment for problematic opioid consumption: Short-and long-term outcomes and current psychological functioning AK Davis, JP Barsuglia, AM Windham-Herman, M Lynch, M Polanco Journal of psychedelic studies 1 (2), 65-73, 2017 | 53 | 2017 |
| A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder JP Barsuglia, M Polanco, R Palmer, BJ Malcolm, B Kelmendi, T Calvey Progress in brain research 242, 121-158, 2018 | 38 | 2018 |
| Neuropsychological and neuroanatomical correlates of the social norms questionnaire in frontotemporal dementia versus Alzheimer’s disease H Panchal, P Paholpak, G Lee, A Carr, JP Barsuglia, M Mather, ... American Journal of Alzheimer's Disease & Other Dementias® 31 (4), 326-332, 2016 | 36 | 2016 |
| A scale of socioemotional dysfunction in frontotemporal dementia JP Barsuglia, NC Kaiser, SS Wilkins, SJ Karve, RJ Barrows, P Paholpak, ... Archives of Clinical Neuropsychology 29 (8), 793-805, 2014 | 32 | 2014 |
| Evaluation of emotional blunting in behavioral variant frontotemporal dementia compared to Alzheimer's disease S Karve, JP Barsuglia, MJ Mather, EE Jimenez, J Shapira, MF Mendez Dementia and geriatric cognitive disorders 38 (1-2), 79-88, 2014 | 31 | 2014 |
| A mixed-method analysis of persisting effects associated with positive outcomes following ibogaine detoxification AK Davis, E Renn, AM Windham-Herman, M Polanco, JP Barsuglia Journal of Psychoactive Drugs 50 (4), 287-297, 2018 | 25 | 2018 |
| Person-based versus generalized impulsivity disinhibition in frontotemporal dementia and Alzheimer disease P Paholpak, AR Carr, JP Barsuglia, RJ Barrows, E Jimenez, GJ Lee, ... Journal of Geriatric Psychiatry and Neurology 29 (6), 344-351, 2016 | 21 | 2016 |
| Executive abilities as reflected by clock hand placement: frontotemporal dementia versus early-onset Alzheimer disease RJ Barrows, J Barsuglia, P Paholpak, D Eknoyan, V Sabodash, GJ Lee, ... Journal of Geriatric Psychiatry and Neurology 28 (4), 239-248, 2015 | 21 | 2015 |
| A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders TJ Camlin, D Eulert, A Thomas Horvath, SF Bucky, JP Barsuglia, ... Journal of Psychedelic Studies 2 (1), 24-35, 2018 | 19 | 2018 |
| Observational themes of social behavioral disturbances in frontotemporal dementia JP Barsuglia, FR Nedjat-Haiem, JS Shapira, C Velasco, EE Jimenez, ... International psychogeriatrics 26 (9), 1475-1481, 2014 | 19 | 2014 |
| Rich club network analysis shows distinct patterns of disruption in frontotemporal dementia and Alzheimer’s disease M Daianu, N Jahanshad, JE Villalon-Reina, MF Mendez, G Bartzokis, ... Computational Diffusion MRI: MICCAI Workshop, Boston, MA, USA, September …, 2014 | 16 | 2014 |
| Characterization of mystical experiences occasioned by 5-MeO-DMT-containing toad bufotoxin and comparison with prior psilocybin studies J Barsuglia, A Davis, R Palmer, R Lancelotta, M Windham-Herman, ... Psychedelic Science 23, 2017 | 8 | 2017 |
| 5-MeO-DMT and subjective improvements in post traumatic stress disorder KE Cox, R Lancelotta, J Barsuglia, AK Davis annual conference of the Maryland Psychological Association, Baltimore, MD, 2018 | 6 | 2018 |
| 5-MeO-DMT for post-traumatic stress disorder: a real-world longitudinal case study A Ragnhildstveit, R Khan, P Seli, LC Bass, RJ August, M Kaiyo, N Barr, ... Frontiers in Psychiatry 14, 1271152, 2023 | 4 | 2023 |
| Subjective improvements in substance use problems following 5-MeO-DMT use in an international sample KE Cox, SA Moshman, JP Barsuglia, R Lancelotta, AK Davis BPRU Poster Symposium, Baltimore, MD, 2018 | 2 | 2018 |
Frances Nedjat-HaiemAssistant Professor, San Diego State University, School of Social WorkVerified email at sdsu.edu
